144 results about "Neural Ganglion" patented technology

The present disclosure describes methods and apparatus for renal neuromodulation via stereotactic radiotherapy for the treatment of hypertension, heart failure, chronic kidney disease, diabetes, insulin resistance, metabolic disorder or other ailments. Renal neuromodulation may be achieved by locating renal nerves and then utilizing stereotactic radiotherapy to expose the renal nerves to a radiation dose sufficient to reduce neural activity. A neural location element may be provided for locating target renal nerves, and a stereotactic radiotherapy system may be provided for exposing the located renal nerves to a radiation dose sufficient to reduce the neural activity, with reduced or minimized radiation exposure in adjacent tissue. Renal nerves may be located and targeted at the level of the ganglion and / or at postganglionic positions, as well as at pre-ganglionic positions.

A method for modulating nerve tissue in a body of a patient includes implanting a wireless stimulation device in proximity to a dorsal root ganglion or an exiting nerve root such that an electrode, circuitry and a receiving antenna are positioned completely within the body of the patient. An input signal containing electrical energy and waveform parameters is transmitted to the receiving antenna(s) from a control device located outside of the patient's body via radiative coupling. The circuitry within the stimulation device generates one or more electrical impulses and applies the electrical impulses to the dorsal root ganglion or the exiting nerve roots through the electrode.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and / or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.

Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and / or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

The invention belongs to the field of organic synthesis and medicines, in particular to application of an N-[4-(monohydro-pyrazol-4-) phenyl]-2,3-dihydro-1,4-benzdioxan-2-amide derivative in preparing a drug for treating glaucoma. In the invention, experiments prove that the N-[4-(monohydro-pyrazol-4-) phenyl]-2,3-dihydro-1,4-benzdioxan-2-amide derivative shown by a formula I has better action of lowering intraocular pressure and protecting ganglion cells, can take the dual effects of protecting optic nerves and RGC (Retinal Ganglion Cells) while lowering the intraocular pressure and provides a new selection for preparing the drug for treating the glaucoma.

The invention provides a compound tFNA-miR22 for treating optic nerve diseases. The compound tFNA-miR22 is composed of a DNA tetrahedron and miR22 according to the molar ratio of 1:(1-4). The tFNA-miR22 disclosed by the invention can be used for effectively inhibiting the apoptosis of the retinal ganglion cells and promoting the release of brain-derived neural factors (BDNF), so that the tFNA-miR22 has a good protection effect on the retinal ganglion cells. The tFNA-miR22 is used for preparing the optic nerve protection medicine, treatment of neurodegenerative optic nerve diseases including glaucoma is facilitated, and the tFNA-miR22 has a very good application prospect.

The invention provides a novel method of treating a diseases associated with apoptotic degeneration in an ocular cell tissue by effectively administering pigment epithelium-derived factor (PEDF). Attentions are focused on PEDF as a novel means of preventing neural ganglion death which is the final pathological stage in glaucoma. Further, attentions are paid to an SIV vector as an effective method of delivering PEDF and an SIV-PEDF vector is constructed. When the SIV-PEDF vector is subretinally administered to an ischemic reperfusion model and an NMDA-induced model, it is observed that neural ganglion death is remarkably inhibited. Thus, it is found out that the SIV-PEDF vector is efficacious as a drug for treating a diseases associated with apoptotic degeneration in an ocular cell tissue such as glaucoma.

6-[18F]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]PSMA-1007 and [Al18F]HBED-CC-PSMA. Unexpectedly, the 6-[18F]fluoro-2-alkoxy and 6-[18F]fluoro-4-alkoxy substituted analogs showed significant differences in accumulation in PSMA expressing prostate tumor cells. Whereas the 2-alkoxy derivative showed cellular uptake values higher than [18F]DCFPyL, the cellular uptake of the corresponding 4-alkoxy substituted derivative was significantly lower. Furthermore, in vivo PET studies with 2-alkoxy-substituted probes demonstrated excellent visualization of PSMA positive ganglia with extremely high target to background ratio. In contrast, the 4-alkoxy substituted derivatives showed less favorable biodistribution with significantly lower uptake in PSMA positive tissues. Especially, the 18F-labeled 2-methoxy derivate ((2S)-2-({[(1S)-1-carboxy-5-[(6-[18F]fluoro-2-methoxypyridin-3-yl)formamido]pentyl]carbamoyl}-amino)pentanedioic acid) demonstrated exceptional clinical efficiency in detecting small PCa lesions, including those which could not be visualized with [68Ga]HBED-CC-PSMA representing currently the gold standard for the diagnosis of recurrent PCa. Furthermore, this probe is easily accessible on a preparative scale in commercially available automated synthesis modules like GE FASTlab and TRACERlab FX N Pro. Consequently, the novel probe is a valuable tool for the visualization of ganglia and reendothelialization as well as for the diagnosis of glioma, neuropathic pain and atherosclerotic plaques.

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

The invention relates to a recombined membrane-penetrating peptide with a WNK (with no lysine (K)) kinase inhibiting effect. The gene has an amino acid sequence shown in SEQID NO.1. Serving as a specific inhibitor of WNK serine / threonine kinase kinase, the recombined membrane-penetrating peptide can be used for reducing the activity of NKCC1 activated by the WNK kinase after being combined with the WNK kinase, thus specifically reducing the Cl<-> in neuron cells of spinal cord dorsal root ganglion (DRG) and trigeminal ganglion, inhibiting the excitability action of GABA (gamma-amino butyric acid) in the DRG and inhibiting the transfer of pain sense.

The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused on SIV vectors for effective methods for delivering PEDF, and constructed an SIV-PEDF vector. When the SIV-PEDF vector was administered subretinally to an ischemia reperfusion model and NMDA-induced model, a significant suppression effect on ganglion cell death was observed. The present inventors therefore discovered that the SIV-PEDF vector is an effective pharmaceutical agent for treating diseases associated with apoptotic degeneration in ocular tissue cells, such as glaucoma.

The invention provides methods for treating ocular diseases using a recombinant vehicle to express a protein useful in the treatment of ocular disease, with particular preference for use of neurotrophin-4 (NT4) for targeting subpopulations of cells in the retina. A genetically engineered gene transfer vector containing sequences encoding a growth factor such as neurotrophin-4 (NT4) is used to transduce cells of the retinal ganglion cell (RGC) layer, in situ, via administration of the vector intravitreally. Accordingly, methods are disclosed for treating subjects in need thereof by therapeutic protein delivery via a recombinant expression vector, including rescue of photoreceptors by targeting the RGC layer subpopulation of retinal cells.

The invention provides methods for production of gangliosides, e.g., GM1, from cells in culture using, for example, bone marrow cells and neuroblastoma cells. Methods include the treatment of cells with neural induction media and chloroquine, or chloroquine alone in the case of, e.g., human bone marrow cells, neuraminidase or glucosamine, to induce the production of gangliosides, e.g., GM1, in the cells. Also provided are methods of long-term, high density culturing of cells without passaging to produce gangliosides, e.g., GM1. Methods of quantifying gangliosides, e.g., GM1 in cell culture are also provided.

The invention provides a medicine for preventing oxidative stress of retinal ganglion, which is a preparation prepared by taking DNA tetrahedron as active ingredient and adding pharmaceutically acceptable auxiliary materials or auxiliary ingredients. The invention also provides the use of the DNA tetrahedron in the preparation of medicines for preventing oxidative stress and apoptosis of retinal ganglion cells. The use of tFNA to prepare drugs for preventing oxidative stress of retinal ganglion cells will help to treat diseases caused by oxidative stress of retinal ganglion cells including glaucoma, and has a very good application prospect.

The invention provides for methods for delivering a nucleic acid into a peripheral neuron by identifying a target neuron in a dorsal root ganglion and intrathecally delivering a vector comprising the nucleic acid to the dorsal root ganglion neuron. The nucleic acid may encode a neurotrophic factor that may be used to treat a peripheral neuropathy or, in conjunction with a nerve guide conduit, to treat a transected peripheral nerve.